Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J - LARVOL DELTA

Targeting the ApoB100-ENO1 Interaction with Engineered Peptides Attenuates Atherosclerotic Inflammation and Plaque Progression. (PubMed, Transl Res) - "The ApoB100-ENO1 axis is a critical driver of macrophage-mediated inflammation in atherosclerosis. The novel peptide PP3m effectively inhibits this interaction, reducing vascular inflammation and plaque progression without altering lipid levels. PP3m represents a promising therapeutic candidate for cardiovascular disease by targeting residual inflammatory risk through a lipid-independent mechanism."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • APOB • CD68 • CXCL8 • ENO1 • IL6

Cost-Minimization Analysis of Aripiprazole 2-Month Ready-to-Use vs. Other Long-Acting Injectable Antipsychotics: Evidence From Ontario (ISPOR-EU 2025) - "Pharmacokinetic bridging data demonstrates comparable exposure to aripiprazole once-monthly (AOM) with prolonged post dose protection.Objective: To evaluate the economic impact on the Ontario Drug Benefit (ODB) program of funding Ari 2MRTU by comparing annual treatment costs with existing reimbursed LAI antipsychotics for maintenance therapy in adults diagnosed with schizophrenia A cost-minimization model was developed from the ODB perspective over a 1-year time horizon, assuming therapeutic equivalence among comparators...Comparators (AOM, risperidone LAI, paliperidone palmitate once monthly [PP1M], and three-monthly [PP3M]) were evaluated per label dosing... These results demonstrate that Ari 2MRTU may deliver cost savings for maintenance treatment of schizophrenia when compared to other LAIs, and this was acrossdifferent initiation scenarios and care settings"

HEOR • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

COST-CONSEQUENCES EVALUATION OF EXTRAPYRAMIDAL SYMPTOMS MANAGEMENT IN SCHIZOPHRENIA: REAL-WORLD COMPARISON OF ORAL ANTIPSYCHOTICS VS LONG-ACTING INJECTABLE ANTIPSYCHOTICS (LAIS) IN BOGOTÁ AND MEDELLÍN, COLOMBIA (WCN 2025) - "LAIs like PP3M demonstrate a superior safety profile, significantly reducing the incidence of EPS compared to oral antipsychotics. They are cost-effective, improving patient quality of life and optimizing healthcare resources. An interdisciplinary approach between psychiatry and neurology is recommended to enhance EPS management and improve clinical and socioeconomic outcomes."

Clinical • Real-world • Real-world evidence • CNS Disorders • Dystonia • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia

Probable seronegative autoimmune psychosis: a case highlighting the diagnostic value of CSF investigation (ECNP 2025) - "The patient's history revealed that she had been treated with paliperidone palmitate 100 mg/month, clozapine (425 mg/day), and valproic acid (1000 mg/day) without clinical improvement over three months. This case underscores the importance of recognizing autoimmune psychosis in psychiatric inpatients with subacute onset and treatment-refractory neurocognitive impairments. It highlights the need to incorporate cerebrospinal fluid analysis and functional neuroimaging into routine diagnostic evaluations in psychiatric settings. In cases where autoantibodies are not detectable, the presence of inflammatory CSF markers and functional imaging abnormalities should prompt early immunotherapeutic intervention, with the potential to prevent diagnostic delays and significantly improve patient outcomes."

Clinical • IO biomarker • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Mental Retardation • Psychiatry • Psychomotor Agitation

COVID-19-Related psychosis and 3-year follow-up: A case report (ECNP 2025) - "During hospitalization, she was treated with intramuscular haloperidol and biperiden, followed by paliperidone palmitate...Due to persistent anhedonia and lack of motivation, sertraline 50 mg/day was added, resulting in full remission...Despite experiencing recurrent episodes, the patient achieved full remission and significant functional recovery. Her complete symptom resolution and reintegration into academic life underscore the importance of future studies to better understand the psychiatric impacts of the pandemic."

Case report • Clinical • CNS Disorders • Mental Retardation • Psychiatry

Measurement of the Personal and Social Performance (PSP) Scale in patients treated with antipsychotics (ECNP 2025) - "Next in line were Ziprasidone (63.0), monthly Paliperidone (61.3), oral Olanzapine (60.9), total Paliperidone use (56.2), three-month Paliperidone (55.3), Risperidone (54.5), and six-month Paliperidone (50.7). At the lower end of our data, Clozapine showed the lowest PSP scores, with an average of 48.7 points... The results suggest that third-generation antipsychotics are associated with better functionality, as measured by the PSP Scale, compared to second-generation antipsychotics. This difference may reflect a more favorable profile of third-generation antipsychotics, with fewer sedative and metabolic side effects, which could contribute to improved quality of life and functioning in patients. It is also important to consider the individual response of patients and adherence to treatment.These findings reinforce our understanding of the superiority of partial agonists such as Aripiprazole and Cariprazine over dopamine antagonists in preserving and restoring patient..."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Risperidone ISM vs Paliperidone Palmitate on a sample of patients affected by schizophrenia: preliminary results from an observational comparative study (ECNP 2025) - "However, patient-reported results indicate some differences, which could depend on the intrinsic characteristics of the two drugs or on demographic or anamnestic differences of the patients. Further studies with larger sample, more homogeneous and comparable cohorts are needed to clarify the underlying reasons for these discrepancies in subjective outcome measures."

Clinical • CNS Disorders • Psychiatry • Schizophrenia • Substance Abuse • DRD2

Impact of paliperidone palmitate 1-month and 3-month long-acting injectable antipsychotics on clinical and psychosocial outcomes in Rwandan patients with schizophrenia (ECNP 2025) - P4 | "Results showed that switching from OAPs to paliperidone palmitate LAI led to statistically significant and clinically meaningful improvements in long-term symptomatic response, psychosocial functioning, patient and clinician satisfaction, and reduction in caregiver burden, in Rwandan patients with schizophrenia."

Clinical • CNS Disorders • Movement Disorders • Psychiatry • Schizophrenia

Paliperidone Palmitate every three months (PP3M) compared to PP1M in people with severe schizophrenia. Treatment outcomes and satisfaction (ECNP 2025) - "Therefore, PP3M formulation allows patients not only to improve treatment outcomes but also to feel more satisfied. Long-term naturalistic studies with larger sample sizes on specific real-world populations must confirm our results."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia

TREATMENT EFFECTS OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS ON NEGATIVE SYMPTOMS OF SCHIZOPHRENIA: A NETWORK INTERVENTION ANALYSIS (WPA-WCP 2025) - "Objectives This prospective cohort study compared the longitudinal trajectories of negative symptom improvement in schizophrenia between three monthly (PP3M) and once monthly (PP1M) paliperidone palmitate formulations, with particular focus on dynamic symptom-network interactions through novel network intervention analysis (NIA). The sex differences observed, with males benefiting more from PP3M, emphasize the need for personalized treatment. These findings provide mechanistic evidence to optimize injection intervals and advance precision psychopharmacology, offering critical insights for refining antipsychotic treatment strategies and improving outcomes in schizophrenia."

CNS Disorders • Psychiatry • Schizophrenia

Successful Transition From Covert, Involuntary Oral Medication to Consensual, Long-Acting, Injectable Antipsychotic Therapy in a Patient With Schizophrenia: A Case Report From Japan. (PubMed, Cureus) - "For three months, his aged father covertly administered oral risperidone...After engaging in shared decision-making focused on the patient's personal recovery goals, such as improving computer skills and living more independently, he consented to therapy with paliperidone palmitate LAI...LAI antipsychotics offer an effective and ethically sound alternative to covert medication in schizophrenia. This approach can strengthen the therapeutic alliance, enhance patient autonomy, and lead to meaningful improvements in clinical symptoms and real-world functioning, providing a valuable solution within challenging sociocultural contexts."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Aerobic Exercise Enhances the Impact of Cognitive Training on Positive Symptoms After a First Episode of Schizophrenia. (PubMed, Behav Modif) - "All participants were also randomly assigned to either oral risperidone or paliperidone palmitate (PP1M) in a concurrent antipsychotic medication study. The two medication groups did not significantly differ on either positive symptom outcome, and there were no three-way interactions. Our findings suggest that the enhancing effect of adding aerobic exercise to cognitive training extends beyond cognitive gains and includes positive psychotic symptoms."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Barriers to transitioning from monthly to 3-monthly paliperidone palmitate formulation: Patient characteristics and physician intentions. (PubMed, Asian J Psychiatr) - No abstract available

Journal

Plasma Protein Patterns Associated with Paliperidone Palmitate Maintenance Therapy in Schizophrenia: A Prospective Cohort Study. (PubMed, CNS Drugs) - "This study reveals transition-associated proteomic signatures in schizophrenia, identifying protein markers that facilitate subgroup stratification and serve as treatment-emergent companion biomarkers to monitor pharmacodynamic shifts during therapeutic transition to PP1M injection therapy."

Journal • CNS Disorders • Psychiatry • Schizophrenia • ANXA1 • ANXA11 • CLEC5A • CRKL

Efficacy and Safety of TV-46000 and Second-Generation Long-Acting Injectable Antipsychotics for Schizophrenia: A Systematic Literature Review and Network Meta-Analysis of Randomized Controlled Trials. (PubMed, Adv Ther) - "TV-46000 q1m and q2m demonstrated comparable efficacy and safety to second-generation LAIs approved in Canada and used for maintenance treatment of schizophrenia."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Pain • Psychiatry • Schizophrenia

Substance Misuse To Psychosis for Stimulants (clinicaltrials.gov) - P2/3 | N=165 | Completed | Sponsor: The University of Hong Kong | Recruiting ➔ Completed | N=240 ➔ 165

Enrollment change • Trial completion • CNS Disorders • Psychiatry • Schizophrenia

Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis. (PubMed, Neuropsychiatr Dis Treat) - P3 | "Long-acting injectable (LAI) formulations of paliperidone palmitate (PP) 1-month-(PP1M), 3-month-(PP3M), and 6-month-(PP6M) have been shown to delay time to relapse and to lower relapse rates, while maintaining symptomatic and functional improvements in patients with schizophrenia. In addition, >56% of patients who transitioned from PP3M to PP6M or continued PP6M treatment had sustained combined (symptomatic and functional) remission at the OLE endpoint. These findings support the long-term efficacy of PP3M and PP6M, highlighting the potential benefits of transitioning to longer acting antipsychotic formulations in achieving and sustaining both symptomatic stability and functional improvement in adults with schizophrenia."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Impacts of Taiwan's National Health Insurance Dedicated Budget Policy on Long-Acting Injectable Usage: An Interrupted Time-Series Analysis (CINP-AsCNP 2025) - "The impact of NHI reimbursement for SGA paliperidone palmitate once-monthly/3-monthly (R-PP1M/R-PP3M) on prescribing was also assessed. The LAI-DBP significantly increased the proportion of antipsychotic prescriptions using any LAI and SGA-LAIs and had a greater impact than R-PP1M and R-PP3M. LAI prescriptions account for approximately one-third of all antipsychotic prescriptions, suggesting that, in addition to financial support, other strategies may be needed to overcome obstacles to their uptake."

Reimbursement • US reimbursement • CNS Disorders • Psychiatry • Schizophrenia

Effectiveness of long-acting injectable paliperidone palmitate on relapse prevention of schizophrenia (CINP-AsCNP 2025) - "Background: Long-acting injectable (LAI) antipsychotics have been widely used in treating people with schizophrenia. Longer half-life of LAI antipsychotics may be more effective in relapse prevention of schizophrenia."

CNS Disorders • Psychiatry • Schizophrenia

Clinical Practice Recommendations for Switching to Longer-Interval Injectable Antipsychotics in Schizophrenia Patients: A Modified Delphi Study in China (CINP-AsCNP 2025) - "Furthermore, the benefits can be amplified in patients who switch from short-interval LAIs, such as paliperidone palmitate one-month formulation (PP1M), to longer-interval LAIs, such as paliperidone palmitate three-month formulation (PP3M) or six-month formulation (PP6M)[3-5]. The findings from the current result support the application of longer-interval LAIs for stable schizophrenia patients. The recommendations aim to optimize the use of longer-interval LAIs and are expected to enhance the outcomes for patients with schizophrenia in China."

Clinical • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

One-Year Evaluation of Paliperidone Palmitate 6-Monthly: Satisfaction and Perceived Effectiveness Among Patients, Relatives, and Clinicians. (PubMed, Patient Prefer Adherence) - "Patient satisfaction and perceived treatment effectiveness play a critical role in healthcare outcomes and overall well-being. Patients, their carers and relatives as well as mental health professionals reported a high satisfaction rate with PP6M, and equally good or even better perceived effectiveness compared to PP1M, PP3M or other oral or LAIs antipsychotics in the majority of cases. Improved patient experience with PP6M could improve treatment continuity and reduce hospitalization rates."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Psychiatric Challenges and Medication Management Following Bariatric Surgery: A Case Report on Bipolar I Disorder (APA 2025) - "Case Presentation The first patient, a 41-year-old Caucasian woman, was stabilized on a regimen that included oral Brexpiprazole at 2 mg, Buspirone at 30 mg twice daily, Mirtazapine at 45 mg, and intramuscular Invega Sustenna at 234 mg, which was later switched to Invega Trinza at 819 mg and Invega Hafyera at 1560 mg...A similar trajectory was observed in a 23-year-old female patient with comorbid generalized anxiety disorder and post-traumatic stress disorder, who was stabilized on Abilify Aristada administered every four weeks, along with sertraline at 150 mg, buspirone at 20 mg twice daily, and propranolol at 30 mg twice daily...Antipsychotic drugs, such as quetiapine and olanzapine, may experience altered bioavailability due to changes in gastrointestinal physiology and first-pass metabolism, causing variable therapeutic responses and a higher risk of adverse effects...The modifications in gastrointestinal structure and function, such as a decrease in gastric..."

Bariatric surgery • Case report • Clinical • Surgery • Bipolar Disorder • CNS Disorders • Gastrointestinal Disorder • General Anxiety Disorder • Mental Retardation • Post-traumatic Stress Disorder • Psychiatry

Achieving Stability With Dual Long Acting Injectable Antipsychotic Medications in Treatment Resistant Psychosis a Case Series (APA 2025) - "The LAIs used were Invega (paliperidone) and Abilify (aripiprazole) in three cases, and Invega and Haldol (haloperidol) in the other three...In the other cases, Invega Sustenna and Abilify Maintena were used simultaneously...The cases in this series highlight LAIs as an important psychopharmacological tool in managing psychosis and potentially transitioning patients out of acute care settings, where they may otherwise be held for weeks, months, or years at a time due to safety concerns and/or a lack of appropriate resources. Furthermore, three of these cases support the use of two second-generation antipsychotics in combination as LAIs, which may be necessary to avoid severe side effects and the effects of long-term use commonly associated with first-generation antipsychotics."

Clinical • Bipolar Disorder • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Real-World Adherence, Healthcare Resource Utilization, And Costs Among Patients With Schizophrenia Utilizing Once-Monthly, Once-Every-Three-Months, And Once-Every-Six-Months Paliperidone Palmitate in the United States (ISPOR 2025) - "OBJECTIVES: Once-every-6-months paliperidone palmitate (PP6M) is the longest dosing interval long-acting injectable (LAI) antipsychotic, followed by once-every-three-months paliperidone palmitate (PP3M). In this real-world descriptive study, patients with schizophrenia using PP3M or PP6M were more adherent, incurred lower medical costs, and a lower proportion had a schizophrenia-related inpatient admission relative to patients using PP1M, suggesting LAIs with longer dosing intervals may improve clinical outcomes and decrease medical costs."

Adherence • Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Psychiatry • Schizophrenia

Treatment Persistence of Paliperidone Palmitate 3-Month in Patients With Schizophrenia: A Japan Medical Data Center Claims Database Analysis. (PubMed, Neuropsychopharmacol Rep) - "Treatment persistence rates for PP3M in Japan were relatively high among schizophrenia patients transitioned from PP1M. High persistence rates can be achieved with PP3M monotherapy in patients who have been sufficiently stabilized with PP1M monotherapy prior to initiating PP3M."

Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia